In addition to combinations of the new proteasome inhibitors with chemotherapy regimens with established performance in MM (including melphalan, prednisone, cyclophosphamide, etc.), trials are underway which involve novel IMiDs, monoclonal antibodies, histone deacetylase inhibitors, cell cycle inhibitors, aurora kinase inhibitors, other kinase inhibitors, heat-shock protein inhibitors, AKT inhibitors, mTORC1 inhibitors, and PARP inhibitors. Here, AKT1 is linked to Miyoshi myopathy.